Lucid Diagnostics Stock Analysis
| LUCD Stock | USD 1.07 0.05 4.90% |
200 Day MA 1.16 | 50 Day MA 1.23 | Beta 1.1 |
Macro event markers
At the current market price of $1.07, LUCD trades below the analyst target price of $4.1. This analysis evaluates LUCD through the lens of intrinsic value estimation. LUCD reports negative return on equity, directing analytical focus toward capital allocation efficiency and the trajectory of shareholder value.
LUCD holds a debt-to-equity ratio of 0.06 relative to health care peers. Based on figures reported as of December 31, 2025, Net Debt remains stable near $-8.88 billion, meaning cash and equivalents exceed total debt — leverage is not a constraint. Also, Net Debt To EBITDA is broadly unchanged at 182.19x. Comparing Lucid Diagnostics' leverage to its own 5-year average reveals whether the current capital structure is within historical norms or stretched. Asset vs Debt
Equity vs Debt
Price Book 2.16 | Price Sales 42.73 | Shares Float 125.7 million | Wall Street Target Price 4.1 | Earnings Share -0.69 |
Lucid |
Stock Analysis Notes
About 26.0% of LUCD outstanding shares are owned by corporate insiders. LUCD reported a loss per share of 0.69. Lucid Diagnostics had not issued any dividends in recent years. Latest disclosures for Lucid Diagnostics show $8.18 in Intangibles To Total Assets, $40.4 million in Total Assets, and a Return On Assets of -151.0%.Total Assets | $26.56 million |
Investor Insights and Alerts
For Lucid Diagnostics, investor alerts are designed to highlight developments that deserve a second look before a position in the stock is increased, reduced, or left unchanged. The strongest alert framework is one that makes risk easier to acknowledge before the market fully reprices it.
| Lucid Diagnostics generated a negative expected return over the last 90 days | |
| Lucid Diagnostics has some characteristics of a very speculative penny stock | |
| Lucid Diagnostics has high historical volatility and very poor performance | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| LUCD reported previous year's revenue of $4.71 million. Net Loss for the year was -$58.01 billion with loss before overhead, payroll, taxes, and interest of -$1.96 million. | |
| Lucid Diagnostics currently holds about $34.46 million in cash as of latest reporting with -$46.48 billion of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Lucid Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of LUCD outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Lucid Diagnostics Rating Lowered to Sell at Wall Street Zen |
Largest EPS Surprises
On Lucid Diagnostics, EPS surprise size and direction can reshape short-term return distribution. Consensus estimates aggregate analyst revisions and guidance updates. For this stock, read EPS surprises with profitability quality and forward revisions.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-24 | 2024-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2025-05-12 | 2025-03-31 | -0.1133 | -0.16 | -0.0467 | 41 | ||
2023-05-15 | 2023-03-31 | -0.35 | -0.4 | -0.05 | 14 |
Top Institutional Investors Holding Lucid Stock
At micro-cap scale, institutional coverage and secondary-market liquidity are typically well established. The holder split in Lucid Diagnostics separates passive index allocation from active institutional positioning. Shares outstanding are near 195.25 million. Whether the institutional base is growing or shrinking quarter over quarter matters more than the current snapshot.
| Shares | Sunbelt Securities | 2025-12-31 | 384 K | Lido Advisors, Llc | 2025-12-31 | 383.1 K | Luminus Management, Llc | 2025-12-31 | 371 K | Jane Street Group Llc | 2025-12-31 | 362.6 K | Squarepoint Ops Llc | 2025-12-31 | 342.9 K | First Manhattan Co. Llc | 2025-12-31 | 323.4 K | The Goldman Sachs Group Inc | 2025-12-31 | 289.3 K | Xtx Topco Ltd | 2025-12-31 | 225.5 K | Charles Schwab Investment Management Inc | 2025-12-31 | 224.9 K | Vanguard Group Inc | 2025-12-31 | 5 M | Blackrock Inc | 2025-12-31 | 4.3 M |
Market Capitalization
Lucid Diagnostics carries a small-cap market capitalization of $201.11 million when compared with health care equipment & supplies companies. Associated fundamentals relevant to market cap include about 195.25 million shares outstanding and enterprise value near $247.48 million.Profitability
Profitability analysis for Lucid Diagnostics focuses on how well revenue converts into operating income, net income, and free cash flow. Annual revenue is about 4.71 million. Comparing gross, operating, and net margins isolates where margin strength or pressure originates.| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | -4.18 | -3.98 | |
| Return On Assets | -143.00% | -151.00% | |
| Return On Equity | -530.00% | -504.00% |
Management Efficiency
LUCD has return on total asset (ROA) of -87.2% suggesting that the balance sheet is not generating positive returns. Negative, placing the result below breakeven. Lucid Diagnostics also reports a return on stockholder's equity (ROE) of -710.6%, indicating that the business is consuming rather than creating equity value.| Last Reported | End Of Year Estimate | ||
| Book Value Per Share | 0.11 | 0.18 | |
| Tangible Book Value Per Share | -2.98 | -2.83 | |
| Price Book Value Ratio | 10.16x | 10.67x | |
| Enterprise Value Multiple | 179.91x | 170.92x | |
| Price Fair Value | 10.16x | 10.67x | |
| Enterprise Value | $36.23 million | $32.2 million |
Management execution at Lucid Diagnostics is evaluated by whether strategy, financial discipline, and operating results are moving in the same direction. This analysis evaluates whether leadership is improving the economics of the business in ways that can persist once the operating environment deteriorates.
Operating Margin | Short Long Term Debt | Operating Margin | Short Long Term Debt Total | Pretax Profit Margin |
Technical Drivers
As of the 12th of May 2026, the last recorded price for Lucid Diagnostics is 1.07 per share. Primary technical drivers reflect Risk Adjusted Performance of -0.02, mean deviation of 2.57, and Standard Deviation of 3.94. Quantitative analysis incorporates volatility metrics and price behavior to assess directional bias. Metrics are compared to industry averages to assess relative positioning.Price Movement Analysis - Bollinger Bands
This analysis covers sixty data points across the selected time horizon. The Extended Parabolic SAR indicator is used to determine the direction of Lucid Diagnostics's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.
Insider Trading Activities
Insider disclosures for Lucid Diagnostics show how people closest to the business are behaving as market expectations change. The goal is to tell routine pay-related sales apart from trades that reflect genuine conviction.
Outstanding Bonds
Corporate bonds issued by Lucid Diagnostics matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ALUFP 65 15 JAN 28 Corp BondUS549463AC10 | View | |
| Alcatel Lucent USA Corp BondUS549463AE75 | View | |
| Morgan Stanley Jul Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Predictive Daily Indicators
Intraday indicators for Lucid Diagnostics suit investors who need a shorter decision cycle and tighter control over timing. The best setups combine these signals with strict risk limits, since short-term data can reverse fast when liquidity thins.
Forecast Models
A forecast for Lucid Diagnostics starts with historical data. Prices often signal trend and momentum shifts before fundamentals catch up. The practical edge is not the forecast number itself, but knowing when the data is becoming less predictable.Financial Strength and Earnings Quality Indicators
Lucid Diagnostics financial ratings play a critical role in determining how much Lucid Diagnostics has to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lucid Diagnostics' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | 7,798 | Possible Manipulator | View |
Debt to Cash Allocation
Tracking debt and cash allocation over time can show when Lucid Diagnostics is prioritizing expansion, refinancing, or capital return.
Total debt stands at approximately $25.82 billion with Debt to Equity (D/E) ratio of 0.06. Lucid Diagnostics has a current ratio of 4.46, suggesting that it is liquid enough and is able to pay its financial obligations when due. Lucid Diagnostics' use of debt should be considered alongside its cash position and equity base.Total Assets Over Time
Assets Financed by Debt
Debt finances 67032.0% of LUCD's total assets — a significant share that elevates balance sheet risk.Lucid Diagnostics Debt Ratio | 67032.0 |
Corporate Bonds Issued
Bond maturity for Lucid Diagnostics is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
Lucid Net Debt
Net Debt | $-8.44 billion |
Stock Analysis Methodology
This diagnostic view of Lucid Diagnostics reviews financial stability, profitability, and risk indicators. Balance sheet indicators include debt-to-equity of 0.06 and current ratio of 4.55. Financial distress probability is estimated at 84%, flagging elevated solvency concern.
Lucid Diagnostics metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Current Lucid Analyst Rating Consensus
| Target Price | Consensus | # of Analysts | |
| 4.1 | Strong Buy | 6 | Odds |
Current and historical analyst recommendations for Lucid Diagnostics are summarized from research sources. The consensus for stocks like Lucid Diagnostics is updated as analysts revise their ratings. Professional analyst coverage of Lucid Diagnostics provides individual investors with access to institutional-quality research. The spread between the highest and lowest Lucid price targets reflects the degree of analytical disagreement. A maintained buy rating with a target cut for Lucid Diagnostics often signals deteriorating near-term expectations. The collective analyst view on Lucid provides a useful reference for individual investment decisions.
Lucid Stock Analysis Indicators
Diagnostics snapshot includes 23 indicators such as Begin Period Cash Flow, Total Stockholder Equity, Net Borrowings.
| Begin Period Cash Flow | 22.36 billion | |
| Total Stockholder Equity | 10.94 million | |
| Net Borrowings | 360,000 | |
| Capital Lease Obligations | 1.82 million | |
| Property Plant And Equipment Net | 2.62 billion | |
| Cash And Short Term Investments | 34.7 billion | |
| Net Invested Capital | -19.34 million | |
| Cash | 34.7 billion | |
| 50 Day M A | 1.2342 | |
| Net Interest Income | 364,000 | |
| Total Current Liabilities | 28.58 million | |
| Interest Expense | 22,000 | |
| Stock Based Compensation | 4.39 billion | |
| Common Stock Shares Outstanding | 101.95 million | |
| Total Cashflows From Investing Activities | -197 million | |
| Free Cash Flow | -46.48 billion | |
| Other Current Assets | -35.02 billion | |
| Accounts Payable | 970,000 | |
| Net Debt | -8.88 billion | |
| Other Operating Expenses | 54.35 million | |
| Non Current Assets Total | 2.98 million | |
| Liabilities And Stockholders Equity | 40.45 million | |
| Non Currrent Assets Other | -2.93 billion |
Popular Tools for Lucid Stock analysis
Insider ScreenerFind insiders across different sectors to evaluate their impact on performancePortfolio CenterAll portfolio management and optimization tools to improve performance of your portfoliosIdea OptimizerApply mean-variance optimization to pre-computed thematic ideas and evaluate candidate allocationsTheme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performanceVolatility AnalysisGet historical volatility and risk analysis based on latest market dataPortfolio DashboardPortfolio dashboard that provides centralized access to all your investmentsPortfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfoliosETFsFind actively traded Exchange Traded Funds (ETF) from around the worldFundamental AnalysisView fundamental data based on most recent published financial statements